Lakefront Biotherapeutics (LKFT) EBT Margin (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of EBT Margin data on file, last reported at 215.34% in Q1 2026.

• EBT Margin for Q1 2026 came in at 215.34%, up 42389.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 44.6% (up 11650.0% YoY), and the FY2025 annual result was 27.05%, up 2817.0% from the prior year.
• EBT Margin improved to 215.34% in Q1 2026 per LKFT's latest filing, from 86.94% in the prior quarter.
• Over five years, EBT Margin peaked at 240.09% in Q2 2025 and troughed at 678.28% in Q3 2025.
• A 5-year average of 36.11% and a median of 13.96% in 2023 frame the typical range for EBT Margin.
• On a YoY basis, EBT Margin climbed as much as 43193 bps in 2025 and fell as far as 62101 bps in 2025.
• A 5-year view of EBT Margin shows it stood at 37.47% in 2022, then tumbled by 121 bps to 7.86% in 2023, then jumped by 746 bps to 50.75% in 2024, then jumped by 71 bps to 86.94% in 2025, then soared by 148 bps to 215.34% in 2026.
• Business Quant data shows LKFT's EBT Margin at 215.34% in Q1 2026, 86.94% in Q4 2025, and 678.28% in Q3 2025.